Empozin-M Tablet 12.5 mg / 500mg

About Empozin-M Tablet 12.5 mg / 500mg

Empozin-M Tablet Uses

• Type 2 diabetes mellitus, when metformin alone does not control blood sugar
• Combination therapy to reduce blood sugar and support weight management
• Used in adults with type 2 diabetes and existing heart disease to lower cardiovascular risk

Empozin-M Tablet Benefits

• Combines two different mechanisms in a single tablet for stronger blood sugar control
• Empagliflozin component removes extra sugar through urine
• Metformin component lowers sugar production by the liver
• May support modest weight loss compared to some other diabetes medicines
• Shown to lower cardiovascular death risk in high risk diabetic patients

What Experts Say

This tablet pairs two medicines that act in different parts of the body. Empagliflozin blocks sugar reabsorption in the kidneys, so extra glucose leaves the body through urine instead of staying in the blood. Metformin lowers how much sugar the liver releases into the bloodstream.

Using both together targets blood sugar from two directions at once, which often gives stronger control than either medicine alone at a similar dose. This combined action also explains why some patients notice modest weight loss, since excess sugar and its calories are lost through urine rather than stored as fat.

Both components carry distinct risks that need regular monitoring. The kidney acting component can cause dehydration, low blood pressure, and genital yeast infections. The liver acting component carries a rare but serious risk of lactic acidosis, especially when kidney function is already reduced.

Drug Class

• Sodium glucose co-transporter 2 (SGLT2) inhibitor combined with a biguanide

Empozin-M Tablet 12.5 mg / 500mg formula

• Empagliflozin + Metformin Hydrochloride

Available forms

• Tablet

How to use Empozin-M Tablet 12.5 mg / 500mg?

• One tablet with meals, usually twice daily as directed
• Whole tablet swallowed, not crushed or chewed
• Adequate water through the day to reduce dehydration risk
• No stopping before surgery without your doctor's advice
• Regular follow up for kidney function and blood sugar checks

Drug Interactions

• Diuretics: Increase the risk of dehydration and low blood pressure when combined.
• Insulin and Sulfonylureas: Raise the risk of hypoglycemia when used together.
• Iodinated Contrast Dye: Metformin should be paused around imaging tests using contrast dye due to kidney related risk.
• Alcohol: Increases the risk of lactic acidosis and low blood sugar.
• Corticosteroids: May raise blood sugar and reduce the medicine's effect.

Risks and warnings

• Lactic Acidosis: Rare but serious risk from the metformin component, higher in kidney or liver impairment.
• Ketoacidosis: Empagliflozin can trigger diabetic ketoacidosis even with normal blood sugar readings.
• Dehydration: Increased urination can lower blood pressure and cause dehydration, especially in older adults.
• Genital Infections: Raises risk of yeast infections and urinary tract infections.
• Kidney Function: Requires monitoring before starting and periodically during treatment.
• Vitamin B12: Long term metformin use may lower vitamin B12 levels.

Empozin-M Tablet 12.5 mg / 500mg Side Effects

• Urinary tract infections
• Genital yeast infections
• Increased urination
• Nausea
• Diarrhea or stomach upset
• Low blood pressure or dizziness
• Increased thirst
• Metallic taste in the mouth
• Vitamin B12 deficiency with long term use

Storage Conditions

• Store below 30°C in a dry place
• Keep the strip inside its original pack away from light
• Keep out of reach of children
• Do not use beyond the printed expiry date